RVMDRevolution Medicines, Inc.Signing up patients
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Non-Small Cell Lung Cancer, NSCLC · KRAS, NRAS, HRAS-mutated NSCLC · KRAS G12C-mutated Solid Tumors, Lung Cancer · Lung Cancer Stage IV, Advanced Solid Tumor, Cancer · RAS G12D-mutated NSCLC
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 616 (planned)
- Started
- Jan 18, 2024
- Main results expected
- Jun 2027
- Fully finished
- Dec 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Adverse events
Measured over: Up to 5 years
Dose limiting toxicities
Measured over: 21 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06162221 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC